Edition:
United Kingdom

Supernus Pharmaceuticals Inc (SUPN.OQ)

SUPN.OQ on NASDAQ Stock Exchange Global Market

43.50USD
16 Aug 2018
Change (% chg)

$0.25 (+0.58%)
Prev Close
$43.25
Open
$43.30
Day's High
$44.00
Day's Low
$43.15
Volume
163,120
Avg. Vol
220,683
52-wk High
$61.25
52-wk Low
$33.45

Chart for

About

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In... (more)

Overall

Beta: 1.30
Market Cap(Mil.): $2,149.64
Shares Outstanding(Mil.): 50.70
Dividend: --
Yield (%): --

Financials

  SUPN.OQ Industry Sector
P/E (TTM): 21.31 30.93 32.76
EPS (TTM): 1.99 -- --
ROI: 50.40 15.07 14.61
ROE: 61.13 16.59 16.33

BRIEF-Supernus Pharma Reports Q1 Earnings Per Share $0.49

* SUPERNUS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND RECORD QUARTERLY REVENUE

08 May 2018

BRIEF-Supernus Announces Pricing Of $350 Mln Private Offering Of 0.625 Pct Convertible Senior Notes

* SUPERNUS ANNOUNCES PRICING OF $350 MILLION PRIVATE OFFERING OF 0.625% CONVERTIBLE SENIOR NOTES

15 Mar 2018

BRIEF-Supernus Announces Proposed Private Offering Of $350 Million Of Convertible Senior Notes

* SUPERNUS ANNOUNCES PROPOSED PRIVATE OFFERING OF $350 MILLION OF CONVERTIBLE SENIOR NOTES

13 Mar 2018

BRIEF-Supernus Reports Q4 Earnings Per Share ‍$0.26​

* SUPERNUS ANNOUNCES RECORD FULL YEAR 2017 FINANCIAL RESULTS, EXCEEDING OPERATING EARNINGS GUIDANCE

27 Feb 2018

Competitors

Earnings vs. Estimates